Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity

被引：7
|
作者：
Chunduri, HimaBindu [2 ]
Crumpacker, Clyde [3 ]
Sharma, Prem L. [1 ,2 ]
机构：
[1] Emory Univ, Dept Microbiol & Immunol, Sch Med, Atlanta, GA 30033 USA
[2] Vet Affairs Med Ctr, Atlanta, GA 30033 USA
[3] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
来源：
VIROLOGY | 2011年 / 414卷 / 01期
关键词：
Replication; Attenuation; RT mutation; K65R; Lys65Arg; K65N; Lys65Asn; HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-RESISTANCE MUTATIONS; 1ST-LINE ANTIRETROVIRAL THERAPY; THYMIDINE ANALOG MUTATIONS; NUCLEOCAPSID PROTEIN; MOLECULAR-MECHANISMS; COMBINATION THERAPY; INFECTED ADULTS; ENZYME FUNCTION; CELL-CULTURE;
D O I：
10.1016/j.virol.2011.03.007
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
In addition to K65R, the other mutation observed at HIV-1 RT codon 65 is K65N. While K65N appears to have a phenotypic effect similar to K65R, it is less frequent during clinical trials. We compared the relative impact of K -> N with respect to K -> R change on viral replication capacity (RC). Mutant viruses were created and replication kinetics assays were performed in PBM cells. Analysis of RCs revealed a significant loss in replication (p=0.004) for viruses containing K65N mutation in comparison to those with K65R mutation. RI processivity assays showed a significant decrease in the processivity of K65N RI in comparison to K65R RT. We demonstrated that the significant decrease in RC of K65N viruses is related to the impaired RI processivity of K65N RI in comparison to K65R, and that the selection of the K65R mutation may be favored in clinical use of antiretroviral drugs compared to K65N. Published by Elsevier Inc.
引用
收藏
页码：34 / 41
页数：8
相关论文
共 50 条
  • [1] The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase
    Arion, D
    Borkow, G
    Gu, ZG
    Wainberg, MA
    Parniak, MA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (33) : 19860 - 19864
  • [2] HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation
    Boucher, S.
    Recordon-Pinson, P.
    Ragnaud, J. M.
    Dupon, M.
    Fleury, H.
    Masquelier, B.
    HIV MEDICINE, 2006, 7 (05) : 294 - 298
  • [3] Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1
    Segondy, M
    Montes, B
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (01) : 110 - 111
  • [4] Prevalence of the K65R Resistance Reverse Transcriptase Mutation in Different HIV-1 Subtypes in Israel
    Turner, Dan
    Shahar, Eduardo
    Katchman, Eugene
    Kedem, Eynat
    Matus, Natasha
    Katzir, Michal
    Hassoun, Gamal
    Pollack, Shimon
    Kessner, Rivka
    Wainberg, Mark A.
    Avidor, Boaz
    JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (09) : 1509 - 1512
  • [5] Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization
    Kagan, RM
    Merigan, TC
    Winters, MA
    Heseltine, PNR
    ANTIVIRAL THERAPY, 2004, 9 (05) : 827 - 828
  • [6] A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine
    Ross, LL
    Dretler, R
    Gerondelis, P
    Rouse, EG
    Lim, ML
    Lanier, ER
    AIDS, 2006, 20 (05) : 787 - 789
  • [7] The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations
    White, KL
    Chen, JM
    Feng, JY
    Morgot, NA
    Ly, JK
    Ray, AS
    MacArthur, HL
    McDermott, MJ
    Swaminathan, S
    Miller, MD
    ANTIVIRAL THERAPY, 2006, 11 (02) : 155 - 163
  • [8] Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase
    Winston, A
    Pozniak, A
    Mandalia, S
    Gazzard, B
    Pillay, D
    Nelson, M
    AIDS, 2004, 18 (06) : 949 - 951
  • [9] Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase?
    Winston, A
    Pozniak, A
    Gazzard, B
    Nelson, M
    ANTIVIRAL THERAPY, 2003, 8 (03) : U132 - U132
  • [10] The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients
    Winston, A
    Mandalia, S
    Pillay, D
    Gazzard, B
    Pozniak, A
    AIDS, 2002, 16 (15) : 2087 - 2089
12345